Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TLM-001
- Development stage
- Preclinical
- Lead developer
- Tsubota Laboratory
- Administration
- Topical
01
Overview
TLM-001 is an investigational therapeutic candidate being developed by Tsubota Laboratory for the treatment of Meibomian Gland Dysfunction (MGD). MGD is a chronic condition characterized by the obstruction or functional impairment of the meibomian glands, which are responsible for secreting the lipid layer of the tear film; this dysfunction is a primary cause of evaporative dry eye disease. As of early 2024, TLM-001 is in the basic research and preclinical stages of development. Specific details regarding its molecular target, mechanism of action, and chemical modality have not been publicly disclosed by the developer, though it is part of a pipeline focused on innovative ophthalmic solutions.
Beyond the preview
Go deeper on TLM-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLM-001.